Genelux (GNLX)
Develops Olvi-Vec, an oncolytic virus therapy for platinum-resistant ovarian cancer.
$2.53
vs last close−0.08 (−3.26%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 21.76% | 9.84M shares | |
|---|---|---|---|
| 73 holders · as of Jun 30, 2026 | |||
| Insiders | 14.23% | 6.44M shares | |
| 13 holders · as of Sep 2, 2026 | |||
| Strategic holders | 14.86% | 6.72M shares | |
| 2 holders · as of Nov 14, 2025 | |||
| Other | 49.15% | 22.24M shares | |
| remainder | |||
45.25M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
73 holders · 9.84M shares · 13 new positions · 31 increased · 15 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 2.26M | 5.00% | +144.9K | Jul 28, 2026 |
| Vanguard Capital Management LLC | 1.68M | 3.71% | −17.8K | Aug 13, 2026 |
| Bleichroeder LP | 1.38M | 3.05% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 439.6K | 0.97% | +33.7K | Aug 7, 2026 |
| Geode Capital Management, LLC | 439.2K | 0.97% | −14.5K | Aug 12, 2026 |
| CM Management, LLC | 400.0K | 0.88% | +150.0K | Aug 13, 2026 |
| Bank of America Corp /DE/ | 328.8K | 0.73% | +4.9K | Aug 14, 2026 |
| Vanguard Fiduciary Trust Co | 236.3K | 0.52% | −15.3K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 4.22M | 13G | Nov 14, 2025 |
| Aladar Szalay | 8.20% | 3.13M | 13G | Feb 17, 2026 |
| Highbridge Capital Management, LLC | 6.80% | 2.50M | 13G | Oct 25, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Yong Yuofficer: Chief Scientific Officer | Sale | 9,683 | $2.75 | 258,688 |
| Aug 31, 2026 | Thomas Zindrickofficer: President and CEO | Sale | 34,463 | $2.67 | 1,226,427 |
| Aug 31, 2026 | Joseph Cappelloofficer: Chief Technical Officer | Sale | 10,257 | $2.74 | 318,480 |
| Aug 4, 2026 | Thomas Zindrickofficer: President and CEO | Sale | 3,023 | $2.95 | 1,260,890 |
| Aug 4, 2026 | Joseph Cappelloofficer: Chief Technical Officer | Sale | 653 | $2.95 | 328,737 |
| Aug 4, 2026 | Yong Yuofficer: Chief Scientific Officer | Sale | 653 | $2.94 | 268,371 |
| Jul 1, 2026 | John W. Smitherdirector | Sale | 12,000 | $2.91 | 91,403 |
| Jun 3, 2026 | Ralph Smallingofficer: Head of Regulatory | Sale | 192 | $2.93 | 67,611 |
| Jun 1, 2026 | John Thomasdirector | Sale | 10,000 | $2.98 | 472,784 |
| May 11, 2026 | Ralph Smallingofficer: Head of Regulatory | Sale | 270 | $2.98 | 67,803 |
House and Senate disclosures
Not reported.